NCT07625358 Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics
| NCT ID | NCT07625358 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University of Singapore |
| Condition | Caffeine |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2027-05-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-06-01 with a primary completion date of 2027-05-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to understand how caffeine and alcohol affect the ocular and physiological systems, especially how the pupil (the aperture in the colored part of the eye) responds to light. It will also test whether these changes can be used to detect recent caffeine or alcohol intake using a portable eye device. The main questions it aims to answer are: 1. How does caffeine change pupil responses, eye movements, and other ocular and physiological measurements? 2. How does alcohol change these same ocular and physiological responses? 3. Are the effects of caffeine and alcohol different from each other? 4. Can these changes be used to accurately identify whether someone has consumed caffeine or alcohol? Researchers will compare caffeine, alcohol, and a placebo (a look-alike drink with no active substance) to see how each affects the ocular and physiological outcomes. Participants will: 1. Attend three separate sessions where they will consume caffeine, alcohol, or a placebo (in random order) 2. Undergo pupillary response evaluation using a handheld device that measures responses to different colored light stimuli 3. Have their eye movements analyzed 4. Have retinal and choroidal thickness, blood perfusion, and ocular oxygen levels measured 5. Have basic body measurements recorded (such as pulse rate and blood pressure) 6. Complete tests at multiple time points over 2 hours after consumption The results of this study may help develop a quick and non-invasive way to detect recent caffeine or alcohol use for clinical and safety purposes.
Eligibility Criteria
Participants must meet the inclusion criteria, as shown below, to participate in this study Inclusion Criteria 1. Age: 30 to 50 years of age 2. Visual Acuity: Best Corrected Visual Acuity (BCVA) of 0.20 LogMAR or better in both eyes 3. Ability to provide informed consent: Participants must be able to understand and sign the informed consent form 4. Ability to consume both caffeine and alcohol: Participants must be willing and able to consume caffeine and alcohol as part of the study Participants meeting any of the exclusion criteria, as shown in the table below, will be excluded from participation. Exclusion Criteria 1. Diagnosed ocular conditions: Participants with ocular or ocular movement diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, amblyopia, severe ptosis, or conditions relating to pupils: anisocoria, irregular pupil, Adie tonic, Horner's syndrome, Argyll Robertson pupil, etc. These exclude cataracts, refractive errors, and any ocular condition not affecting vision or ocular movement or obstructing the pupil. 2. Diagnosed and unresolved neurological conditions:Stroke, unresolved traumatic brain injury, space-occupying lesions in the brain, neuropathies, demyelinating conditions, nerve palsies, etc. 3. Diagnosed systemic conditions that may restrict the participant from drinking caffeine or alcohol: Hypertension, cardiovascular disease, liver disease, kidney disease, etc. 4. Medications: Participants taking any medications that may interact with caffeine or alcohol, affect alertness, or cause drowsiness 5. Previous complex intraocular eye surgery: Participants who have undergone any eye surgery other than uncomplicated refractive surgery. 6. Pregnancy or breastfeeding: Pregnant or breastfeeding women will be excluded from the study, as caffeine and alcohol can affect the fetus or baby 7. History of substance abuse: Participants with a history of substance abuse 8. Allergies or sensitivities: Participants with allergies or sensitivities to caffeine or alcohol 9. Shift work or having travelled across 2 time zones over the past 2 weeks: This is essential to avoid any impact of sleep deprivation on our outcome measures 10. Non-consumers or light-consumers of caffeine and alcohol Participants who are light consumers of caffeine or alcohol will be excluded due to higher sensitivity to side effects. Caffeine: If less than 100 mg of caffeine per week from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\* Alcohol: If AUDIT-C\*\* score less than 1 11- Extremely frequent consumers Participants who are extremely frequent consumers of caffeine or alcohol will be excluded due to potential withdrawal symptoms during the required 18-hour abstinence and possible reduced sensitivity to administered doses. Caffeine: If more than 400mg of caffeine (e.g., 5 espressos) per day from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\* Alcohol: If AUDIT-C\*\* scores more than 4 for men and more than 3 for women Note: Participants will complete a history update questionnaire at each laboratory visit to report any changes relevant to the exclusion criteria. If a participant no longer meets the eligibility criteria at any visit after the baseline assessment, the visit will either be rescheduled, if appropriate, or the participant will be withdrawn from the study. Reimbursement will be provided on a prorated basis. \*CCQ: Caffeine Consumption Questionnaire \*\*AUDIT-C: Alcohol Use Disorders Identification Test-C
Contact & Investigator
Raymond P. Najjar, PhD
PRINCIPAL INVESTIGATOR
Department of Ophthalmology, National University of Singapore (NUS)
Frequently Asked Questions
Who can join the NCT07625358 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 50 Years, studying Caffeine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07625358 currently recruiting?
Yes, NCT07625358 is actively recruiting participants. Contact the research team at tv96@nus.edu.sg for enrollment information.
Where is the NCT07625358 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07625358 clinical trial?
NCT07625358 is sponsored by National University of Singapore. The principal investigator is Raymond P. Najjar, PhD at Department of Ophthalmology, National University of Singapore (NUS). The trial plans to enroll 100 participants.